Document is current
Any future updates will be listed below
-
Authors
Tullis, Jonathan E.
Bayer, K. Ulrich
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (T32 GM007635)
National Institute of Neurological Disorders and Stroke (R01 NS081248)
National Institute on Aging (R01 AG067713)
- License Information
-
More Information
Article History
Received: 5 March 2024
Accepted: 4 July 2024
First Online: 9 July 2024
Competing interests
: K.U.B. is co-founder and board member of Neurexis Therapeutics, a company that seeks to develop a CaMKII inhibitor into a therapeutic drug for cerebral ischemia. J.E.T. has no competing interests to declare.
